Cargando…
Novel longitudinal Multiple Overall Toxicity (MOTox) score to quantify adverse events experienced by patients during chemotherapy treatment: a retrospective analysis of the MRC BO06 trial in osteosarcoma
OBJECTIVES: This study aims at exploring and quantifying multiple types of adverse events (AEs) experienced by patients during cancer treatment. A novel longitudinal score to evaluate the Multiple Overall Toxicity (MOTox) burden is proposed. The MOTox approach investigates the personalised evolution...
Autores principales: | Spreafico, Marta, Ieva, Francesca, Arlati, Francesca, Capello, Federico, Fatone, Federico, Fedeli, Filippo, Genalti, Gianmarco, Anninga, Jakob, Gelderblom, Hans, Fiocco, Marta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679129/ https://www.ncbi.nlm.nih.gov/pubmed/34916320 http://dx.doi.org/10.1136/bmjopen-2021-053456 |
Ejemplares similares
-
Method to measure the mismatch between target and achieved received dose intensity of chemotherapy in cancer trials: a retrospective analysis of the MRC BO06 trial in osteosarcoma
por: Lancia, Carlo, et al.
Publicado: (2019) -
Short-term and long-term prognostic value of histological response and intensified chemotherapy in osteosarcoma: a retrospective reanalysis of the BO06 trial
por: Musta, Eni, et al.
Publicado: (2022) -
Disease progression in osteosarcoma: a multistate model for the EURAMOS-1 (European and American Osteosarcoma Study) randomised clinical trial
por: Hazewinkel, Audinga-Dea, et al.
Publicado: (2022) -
A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup
por: Lancia, Carlo, et al.
Publicado: (2019) -
MRC2020: improvements to Ximdisp and the MRC image-processing programs
por: Short, J. M., et al.
Publicado: (2023)